Oxidative stress (OxS) is considered a major factor in the pathophysiology of inflammatory
chronic liver diseases, including non-alcoholic liver disease (NAFLD). Chronic impairment of …

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both
manifestations of end-organ damage of the metabolic syndrome. Through multiple …

Background & Aims The development of hepatic models capable of long-term expansion
with competent liver functionality is technically challenging in a personalized setting. Stem …

Non-alcoholic fatty liver (NAFLD) is the most common liver disease worldwide, progressing
from simple steatosis to necroinflammation and fibrosis (leading to non-alcoholic …

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver
diseases worldwide, causing considerable liver-related mortality and morbidity. During the …

The global prevalence of nonalcoholic fatty liver disease (NAFLD) continues to rise, yet
effective treatments are lacking due to the complex pathogenesis of this disease. Although …

Background Metformin is first‐line therapy for patients with diabetes. However, it may lower
vitamin B12 concentrations, which could have hematological or neurological implications …

Non-alcoholic fatty liver disease (NAFLD) is a challenging disease caused by multiple
factors, which may partly explain why it still remains an orphan of adequate therapies. This …

Non-alcoholic fatty liver disease (NAFLD) is a disease that is prevalent worldwide, and its
prevention by dietary administration has recently been considered as an important strategy …

There are no licensed drugs for nonalcoholic fatty liver disease (NAFLD), and there is a lack
of consensus on the best outcome measures for controlled trials. This systematic review …